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Renal cancer surgeons are acutely aware of the pre-eminent data from the 25 
immunotherapy era demonstrating a significant survival advantage for patients with 26 
metastatic renal cell cancer (mRCC) having cytoreductive nephrectomy (CNx) prior to 27 
IFN-alpha treatment [1,2].  However, oncological treatments given to patients with 28 
mRCC have radically changed in the current era where pan-tyrosine kinase inhibitors 29 
(TKIs) and those specifically targeting VEGF or mTOR are used. In 2009/2010 the 30 
urological surgery community widely supported the launch of two randomised 31 
controlled trials that aimed to assess the place of CNx in mRCC patients treated with 32 
TKIs, as well as assessing the timing of the CNx in relation to TKI administration. In 33 
the French CARMENA trial (NCT00930033), patients were to be randomised to CNx 34 
and sunitinib vs sunitinib alone without CNx (supplemental figure 1).  In the EORTC 35 
sponsored SURTIME trial (EORTC 30073; NCT01099423), the sequencing of drug 36 
and surgical therapies was to be assessed. Patients were randomised to sunitinib 37 
followed by CNx and subsequent sunitinib vs CNx followed by sunitinib (supplemental 38 
figure 2).  However, recruitment to these two studies has proven to be hugely 39 
challenging. 40 
After initial robust recruitment in France, CARMENA was opened to recruitment in the 41 
UK in May 2011. A total of 26 sites around the UK were opened for CARMENA 42 
recruitment. However, in 2014 CARMENA was closed to recruitment in the UK, as 43 
over four years only 14 patients were recruited. However, the CARMENA study does 44 
continue to recruit slowly in France (411 of 576 patients recruited) and it is likely to 45 
complete recruitment in September 2017; the study is estimated to end 6 years later 46 
than originally planned. In an attempt to try and determine why this study failed to 47 
recruit in a nation with robust trials infrastructure an investigator questionnaire was 48 
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sent to the UK investigators. Responses indicated that there was a lack of patient and 49 
clinician equipoise and inability of the clinical team to convince patients to be 50 
randomised (see box 1). Within the investigator questionnaire, 34 varied mRCC 51 
clinical scenarios were described, with investigators asked if they would recommend 52 
surgery, drug treatment, best supportive care or entry into CARMENA. Of the 17 53 
respondents (65% response rate), the 5 urologists gave a median of 20 of the 54 
scenarios (range=11-22) where their preferred management strategy would be 55 
CARMENA and the 12 oncologists gave a median of 8.5 CARMENA scenarios 56 
(range=6-19). Thus urologists appeared to have greater levels of equipoise for the 57 
study. However, if there is one key individual within the clinical team who lacks 58 
equipoise this is usually transferred to the patient making recruitment more 59 
challenging.  60 
The SURTIME study has also been hugely challenging with poor recruitment in many 61 
centres. Efforts were made by the EORTC to improve accrual by online education 62 
tools and regular updates. Accrual was strongest in the Netherlands and Canada and 63 
best in centres with a main focus on RCC management, where study eligibility was 64 
discussed at multidisciplinary tumour boards with urologists and oncologists together. 65 
However, SURTIME eligibility criteria were complex and were considered among the 66 
main reasons for the poor accrual. This was especially true for smaller centres, where 67 
small numbers of patients precluded experience with the entry criteria from being 68 
gained. In addition, despite surgery and therapy being offered in both arms, it proved 69 
difficult to convince patients to be randomised. The study closed early in 2016 and is 70 
likely underpowered to show differences in the primary and secondary endpoints of 71 
PFS and OS but may answer the question of rapid progression after pretreatment and 72 
interruption for surgery.  73 
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As such, the main hope for level 1 evidence regarding the place of CNx in metastatic 74 
kidney cancer in the TKI era comes from recruitment to CARMENA study by the 75 
French team. However, there are some concerns that this study will only answer the 76 
question of whether both arms are “equivalent”; 1134 patients would need to be 77 
recruited to be able to determine if either arm was deleterious. As such, it maybe that 78 
lower levels of evidence, which suggest CNx is beneficial in selected situation such as 79 
those patients predicted to have greater than 1 year life expectancy, are the best we 80 
will have to answer this common clinical dilemma [3]. Concerningly, there is evidence 81 
that CNx utilisation is now underutilised, especially in non-academic centres, Black or 82 
uninsured patients. This underutilisation of CNx was associated with a 10 month worse 83 
survival from mRCC [4]. 84 
However, recruitment issues with surgical trials are not a urology specific 85 
phenomenon. It has been recognised for a number of years that randomised controlled 86 
trials in surgery are exceedingly challenging for a number of reasons [5,6]: surgeon 87 
and patient equipoise, perceived threat to surgeon’s personal interests, lack of 88 
funding, infrastructure and experience in data collection, operative learning curves, 89 
and blinding. Indeed, a recent study revealed that 1 in 5 surgical randomised controlled 90 
trials was stopped early and 1 in 3 completed trials did not publish after a median of 91 
4.9 years [7]. The commonest reason for discontinuation was, as in the example of 92 
SURTIME, poor recruitment.  Numerous initiatives have been tried to improve 93 
recruitment to surgical RCTs and are currently ongoing to improve renal cancer 94 
surgery related trials but it is clear that there is not one solution that will improve the 95 
situation (box 2). As such, in addition to the multiple sensible measures to improve 96 
recruitment once the trial has opened it is now recommended that in any renal cancer 97 
surgery related RCT a feasibility or pilot study in a limited number of patients and 98 
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centres be instigated prior to launching the main trial. The results of successful 99 
feasibility/pilot studies will allow the launch of a fully powered study, may influence the 100 
power calculation for the full study and provide a cadre of engaged urologists to deliver 101 
future clinical trials.  102 
There are signs that in surgery in general the tide is changing in terms of delivery of 103 
successful RCTs [8]. Despite this, as we move into RCC immunotherapy era v2, it is 104 
likely that we will never answer the question of the place of CNx in patients treated 105 
with TKIs.  106 
  107 
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Box 1. Selection of quotes from investigator questionnaire, illustrating lack of 142 
clinician and patient equipoise. 143 
‘Randomisation is difficult and if offered surgery as a possible treatment, most 
patients decided to have it off trial’ 
‘Relatively few patients with clinical equipoise’ 
‘Patient choice was our main failure’ 
‘Patients unwilling to be randomised between surgical and non-surgical option. 
Patients often have strong views as to whether they would want to undergo surgery 
or not in a palliative setting.’ 
‘There was rarely equipoise at MDT discussion’ 
‘Unwillingness to recruit due to surgeon/oncology bias.’ 
‘Many patients I saw either "obviously" needed a nephrectomy or "obviously" 
needed oncology.  I did not want to delay their treatment.’ 
 144 
  145 
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Box 2. Recommendations for future surgery related RCTs 146 
Canvassing of the speciality regarding key questions for clinical trials e.g. using 
Delphi process  
Iterative process of discussion with NCRI Clinical Studies Group during 
development 
Initial pilot or feasibility study (refine recruitment procedures and inform recruiter 
training by: piloting recruitment materials, determine reason for screening failures) 
Consideration of clinical nurse specialist providing information in unbiased manner 
with enough time for full discussion 
Confirm commitment and explicitly make the case for equipoise with potential 
investigators at each site by interview process 
Education and training programme for recruiters  
Ensure clear ‘reward’ process (i.e. authorship rights, research nurse funding) for 
high recruiters 
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